Dosing of Tisagenlecleucel Among Pediatric Patients With Leukemia and Improved Outcomes
Posted: 08/19/2022 | By: Sarah Campen, PharmD

Research published by Stefanski et al in Blood Advances sought to determine the effect of varying doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, across the approved dosing range on survival outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL).

Question 1 of 5

Which patient characteristic was NOT associated with worse overall survival outcomes with tisagenlecleucel therapy?

Choose 1